	US 12,110,318 B2
	Peptide analogs
Sheau Yu Teddy Hsu, Menlo Park, CA (US)
Assigned to Adepthera LLC, Palo Alto, CA (US)
Filed by Adepthera LLC, Palo Alto, CA (US)
Filed on Jun. 10, 2022, as Appl. No. 17/837,736.
Application 17/837,736 is a division of application No. 16/922,850, filed on Jul. 7, 2020, granted, now 11,390,657.
Application 16/922,850 is a division of application No. 16/016,235, filed on Jun. 22, 2018, abandoned.
Claims priority of provisional application 62/527,680, filed on Jun. 30, 2017.
Prior Publication US 2022/0324935 A1, Oct. 13, 2022
Int. Cl. C07K 14/575 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); C07K 14/47 (2006.01); C07K 14/585 (2006.01); C07K 14/655 (2006.01); A61K 9/00 (2006.01)

CPC C07K 14/575 (2013.01) [A61K 45/06 (2013.01); A61K 47/542 (2017.08); A61K 47/60 (2017.08); C07K 14/47 (2013.01); C07K 14/57527 (2013.01); C07K 14/585 (2013.01); C07K 14/655 (2013.01); A61K 9/0019 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)]

7 Claims

1. A Multiple Receptor Ligand (MRL), comprising

(Glp)RPRLSHKGP(Nle)PF-miniPEG-K(PAL)GCRFGTCTVQKLAHQIYQFTDKDVAPRSKISPQGY-NH2 (SEQ ID 228) or (Glp)RPRLSHKGP(Nle)PF-miniPEG-K(gamma-Glu-PAL)GCRFGTCTVQKLAHQIYQFTDKDVAPRSKISPQGY-NH2 (SEQ ID 229), or a pharmaceutically acceptable salt thereof,

wherein miniPEG is —NH(CH₂CH₂O)₂CH₂C(═O)— and Pal is palmitoyl.